SUMO2P8: A Potential Drug Target and Biomarker (G100506244)

Target Name: SUMO2P8

NCBI ID: G100506244

SUMO2P8

Other Name(s): SUMO2 pseudogene 8

SUMO2P8: A Potential Drug Target and Biomarker

SUMO2P8, short for sumoylated alpha-2-positive endoplasmic reticulum protein 8, is a protein that is expressed in various cell types, including neurons, muscle cells, and cancer cells. It is a highly conserved protein that is involved in a variety of cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling pathways.

Recent studies have identified SUMO2P8 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. SUMO2P8 has also been shown to play a role in several cellular processes that are involved in disease development, including the regulation of cell division, cell signaling, and neurotransmission.

One of the key features of SUMO2P8 is itsSumoylation status. Sumoylation is a post-translational modification that involves the addition of a chemical group called a sumoyl group to specific amino acids. This modification has been shown to play a critical role in the regulation of protein structure and function, and is involved in many cellular processes, including cell signaling and protein-protein interactions.

SUMO2P8 is a type of protein that is targeted by several drugs in development, including inhibitors of itsSumoylated state. These drugs work by binding to specificSumoyl groups on SUMO2P8 and preventing them from interacting with other proteins. This can lead to the inhibition of SUMO2P8-mediated signaling pathways and the inhibition of cellular processes that are dependent on SUMO2P8.

In addition to its potential as a drug target, SUMO2P8 has also been identified as a potential biomarker for several diseases. TheSumoylated state of SUMO2P8 is often reduced in certain types of cancer, and this reduction has been shown to be associated with poor prognosis. Additionally, SUMO2P8 has been shown to be involved in the regulation of neurotransmission, and alterations in its expression have been observed in a variety of neurodegenerative diseases.

SUMO2P8 is also involved in the regulation of cell division and has been shown to play a role in the regulation of mitosis. It has been shown to be involved in the distribution of organelles during cell division and in the regulation of the metaphase transition.

In addition to its role in cell division, SUMO2P8 is also involved in the regulation of protein-protein interactions. It has been shown to interact with several proteins, including the transcription factorp53 and the protein tyrosine phosphatase SHP-2. These interactions are involved in the regulation of a variety of cellular processes, including cell signaling and protein-protein interactions.

In conclusion, SUMO2P8 is a protein that is involved in a variety of cellular processes and has been identified as a potential drug target and biomarker for several diseases. ItsSumoylated state and its involvement in cell division, neurotransmission, and protein-protein interactions make it an attractive target for further research and development. Further studies are needed to fully understand the role of SUMO2P8 in disease and to develop effective treatments.

Protein Name: SUMO2 Pseudogene 8

The "SUMO2P8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMO2P8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets